Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the sale, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at $54,081,710.10. This trade represents a 4.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, February 25th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00.

Kymera Therapeutics Stock Down 2.8%

Kymera Therapeutics stock opened at $81.51 on Thursday. Kymera Therapeutics, Inc. has a 52 week low of $28.06 and a 52 week high of $103.00. The company has a market capitalization of $6.65 billion, a price-to-earnings ratio of -22.15 and a beta of 2.28. The stock has a 50-day moving average price of $84.63 and a 200 day moving average price of $76.20.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period last year, the firm earned ($0.88) EPS. The company’s revenue for the quarter was down 60.8% compared to the same quarter last year. Research analysts anticipate that Kymera Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its position in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $63,000.

Analyst Ratings Changes

A number of research firms recently commented on KYMR. Stephens lifted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Wall Street Zen downgraded Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. UBS Group lifted their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, BTIG Research reduced their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.